Sign in
Not yet taking people in United StatesPhase 2

Hyaluronidase injections for tight, thick finger skin in systemic sclerosis

Tests hyaluronidase injections in adults with systemic sclerosis and stiff, tight fingers.

Key facts

Who runs it
Stanford University
Where
Stanford, United StatesSee the site
Trial code
Registry title
Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma
Status
Not yet recruiting
Phase
Phase 2
People taking part
10 people, planned
Starts
1 Dec 2026
Expected to end
Dec 2027
Type of study
Interventional, 2 groups
Treatments tested
  • hyaluronidase
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with scleroderma whose fingers are thick and tight in both hands. One hand gets hyaluronidase injections and the other hand is the untreated comparison.

Age
18 years or older
Sex
All sexes can join
Disease stage
Documented scleroderma with clear thick, tight skin on the fingers (sclerodactyly) in both hands.

Main reasons for not taking part

  • Not able to give written informed consent
  • No sclerodactyly in both hands, so treatment and comparison are not possible
  • Known allergy to hyaluronidase or any part of the study drug
  • Active infection, acute inflammation or another problem at an injection site that makes injection unsafe
  • Pregnancy or expected pregnancy

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Adults aged 18 years or older
  • Documented diagnosis of scleroderma
  • Clinically evident bilateral sclerodactyly involving both hands,
  • Able and willing to comply with study visits and assessments
  • Able to provide written informed consent

Who cannot take part

  • Known hypersensitivity to hyaluronidase or any component of the study drug
  • Active infection, acute inflammation, or another condition at a planned injection site that would make intradermal injection unsafe
  • Age younger than 18 years
  • Unable to provide informed consent
  • Absence of bilateral sclerodactyly sufficient to permit treatment and comparison
  • Pregnancy or anticipated pregnancy
  • Declines participation

Where in United States

  • Stanford UniversityStanford, United StatesContact: Winnie Fan, MDNot yet recruiting

About the trial

What the trial wants to find out

Systemic sclerosis can cause the skin of the fingers to become thick and tight, a condition called sclerodactyly. This can make it difficult to bend, straighten, and use the fingers. This study will evaluate whether intradermal injections of hyaluronidase (Amphadase) can improve hand mobility and function and will assess treatment-related side effects.

Read full original descriptionShow less

Approximately 10 adults with systemic sclerosis and sclerodactyly affecting both hands will participate at Stanford University. For each participant, one hand will be randomly selected by coin flip to receive hyaluronidase injections, while the opposite hand will serve as an untreated control. Participants may receive up to four injection sessions at baseline and approximately months 1, 2, and 3. Both hands will receive the same home exercise guidance throughout the study.

Participants will undergo assessments at baseline and months 1, 2, 3, and 6, including hand mobility and skin examinations, hand function questionnaires, and assessment of symptoms and adverse events. Researchers will compare changes between the treated and untreated hands. The investigator performing hand outcome assessments will be blinded to treatment assignment.

The 2 groups in the trial

  • Arm Title: Left Hand Hyaluronidase, Right Hand ControlTreatment being tested

    Participants assigned to this arm will receive intradermal hyaluronidase injections in the left hand, while the right hand serves as an untreated control. Up to four treatment sessions will be administered at approximately monthly intervals. Both hands will undergo standardized assessments throughout the study.

    Treatment: hyaluronidase

  • Right Hand Hyaluronidase, Left Hand ControlTreatment being tested

    Participants assigned to this arm will receive intradermal hyaluronidase injections in the right hand, while the left hand serves as an untreated control. Up to four treatment sessions will be administered at approximately monthly intervals. Both hands will undergo standardized assessments throughout the study.

    Treatment: hyaluronidase

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Intradermal Hyaluronidase for Sclerodactyly in Systemic Sclerosis: A Prospective Split-Hand Controlled Pilot Study
Plain-language title
Hyaluronidase injections for tight, thick finger skin in systemic sclerosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
6 November 2026